Abide’s ABX-1431 Modulates Endogenous Cannabinoid Tone to Treat Neuroinflammation and Neurodegeneration

SAN DIEGO, October 29, 2015 – Abide Therapeutics Developing Endocannabinoid System Modulator With Breakthrough Potential

The medicinal effects of cannabinoids have been recognized for thousands of years – pain, anxiety, epilepsy, and sleep disorders are just a few of the maladies that have been treated using preparations of the Cannabis plant. More recently, researchers have engaged in identifying the pharmacologically active moieties of the hundreds of chemical compounds found in cannabis. Of these, the main psychoactive compound of cannabis, tetrahydrocannabinol (THC), has been shown to bind to the body’s cannabinoid receptors and mediate many of the effects of cannabis that were first discovered by patient self-medication. This “reverse pharmacology drug discovery” approach has allowed the identification of cannabinoid-sensitive diseases like multiple sclerosis, pain, fibromyalgia, neurodegenerative diseases, and certain forms of epilepsy.

Abide is developing a first-in-class, investigational endocannabinoid system modulator, ABX-1431, which increases the natural levels of the endogenous cannabinoid 2-arachidonoylglycerol. Based on compelling preclinical data, it is anticipated that ABX-1431 treatment will enable the more desirable therapeutic effects of cannabinoids, as well as novel anti-inflammatory effects, without triggering the adverse psychoactive effects of THC. A Phase 1a clinical study is underway in Belgium to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of ABX-1431.

Read Brian Owens’ full article in Nature on the potential of cannabinoid compounds

Learn more about Abide’s Phase 1 clinical trial